Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 8
Submit an article Journal homepage
680
Views
13
CrossRef citations to date
0
Altmetric
Review

FLT3 inhibitor quizartinib (AC220)

Kiran NaqviDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
&
Farhad RavandiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
Pages 1866-1876 | Received 02 Nov 2018, Accepted 21 Mar 2019, Published online: 18 Apr 2019

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Alejandro Garcia-Horton & Karen Wl Yee. (2020) Quizartinib for the treatment of acute myeloid leukemia. Expert Opinion on Pharmacotherapy 21:17, pages 2077-2090.
Read now
Felicetto Ferrara & Alessandra Picardi. (2020) Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation?. Expert Review of Hematology 13:2, pages 99-108.
Read now

Articles from other publishers (11)

Sicong Xu, Yiran Zhu, Jie Meng, Chao Li, Zhenzhen Zhu, Chen Wang, Yu-Cheng Gu, Liang Han, Jiajie Wen, Minghui Tong, Xuan Shi, Yunlei Hou, Yajing Liu & Yanfang Zhao. (2023) 2-Aminopyrimidine derivatives as selective dual inhibitors of JAK2 and FLT3 for the treatment of acute myeloid leukemia. Bioorganic Chemistry 134, pages 106442.
Crossref
Moo-Kon Song, Byeong-Bae Park & Ji-Eun Uhm. (2022) Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia. International Journal of Molecular Sciences 23:20, pages 12708.
Crossref
Baku Acharya, Debasmita Saha, Daniel Armstrong, Naga Rajiv Lakkaniga & Brendan Frett. (2022) FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms. RSC Medicinal Chemistry 13:7, pages 798-816.
Crossref
Jennifer C. Zhao, Sonal Agarwal, Hiba Ahmad, Kejal Amin, Jan Philipp Bewersdorf & Amer M. Zeidan. (2022) A review of FLT3 inhibitors in acute myeloid leukemia. Blood Reviews 52, pages 100905.
Crossref
Xiaoyang Yang, Mengjie Wan, Feng Yu & Xiuji Wu. (2021) Histone methyltransferase EZH2 epigenetically affects CCNA1 expression in acute myeloid leukemia. Cellular Signalling 87, pages 110144.
Crossref
Eimear O’Reilly, Hojjat Alizadeh Zeinabad, Caoimhe Nolan, Jamileh Sefy, Thomas Williams, Marina Tarunina, Diana Hernandez, Yen Choo & Eva Szegezdi. (2021) Recreating the Bone Marrow Microenvironment to Model Leukemic Stem Cell Quiescence. Frontiers in Cell and Developmental Biology 9.
Crossref
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu & Christopher J. O’Donnell. (2021) Synthetic Approaches to the New Drugs Approved during 2019. Journal of Medicinal Chemistry 64:7, pages 3604-3657.
Crossref
Jifeng Yu, Peter Y. Z. Jiang, Hao Sun, Xia Zhang, Zhongxing Jiang, Yingmei Li & Yongping Song. (2020) Advances in targeted therapy for acute myeloid leukemia. Biomarker Research 8:1.
Crossref
Jörg P. Müller & Dirk Schmidt-Arras. (2020) Novel Approaches to Target Mutant FLT3 Leukaemia. Cancers 12:10, pages 2806.
Crossref
Na Yoon Kim, Yong-Chul Kim & Yoon Gyoon Kim. (2020) Development of UHPLC-MS/MS Method for Indirubin-3′-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats. Molecules 25:9, pages 2039.
Crossref
Abdulaziz B. Hamid & Ruben C. Petreaca. (2020) Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Cancers 12:4, pages 927.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.